Obermatt

Flags

Financial distress

Amplifon

MIL:AMP · IT0004056880
Health Care Providers & ServicesLarge

360

27
EV / EBIT53
Price / Owner Earnings43
Owner Earnings Yield57
Dividend Yield74
Price/Sales50
EV / Gross Profit38
Price/Book52
Return on Capital59
Cash Return on Capital52
Return on Equity38
EBIT Margin69
Gross Profitability25
Cash Conversion87
Accruals73
Owner Earnings Margin66
Sales growth29
Profit Growth66
Long-Term EPS Growth75
Owner Earnings Growth12
Reinvestment18
Price momentum6
Debt load25
Refinancing16
Debt Payback26
Liquidity46
Analyst ratings12
Opinion Changes56
Price Target Upside58
Market mood18
Value Creation8/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Amplifon clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryItaly
IndustryHealth Care Providers & Services
SizeLarge
TypePublic Company
ExchangeBIT
Employees5,119
ISINIT0004056880
Last UpdateApr 2, 2026
Themes
Ear Nose & Throat (ENT)Assistive TechnologyE-CommerceHealth CareRetail

Description

Amplifon S.p.A. engages in the distribution and customization of fitting of hearing aids for the solution of problems related to the loss of hearing and the supply of related services. Amplifit engages in the diagnosis of hearing problems and in the…

Analysis

Middle-of-the-road

Amplifon S.p.A. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

On valuation, the picture is fair. The owner-earnings multiple stands at 20.7×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 7% a year, against analyst forecasts of 15%. The price, in other words, assumes less than the experts do.

Growth is tepid; the safety picture is adequate. The company scores 8/20 on our value-creation score: creating some value. Analyst sentiment is cautious.

Flags to be aware of: A large part of the company's book value is the price paid for past acquisitions. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
1
2023202420252026

All-time high

54

Mar 2024

All-time low

1

Jun 2026

Average rank

18

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
50
11
7
4
Price/Earnings
53
24
11
4
Price/Book
52
17
12
12
Dividend Yield
74
40
22
24
Value (overall)
54
10
4
1

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Amplifon with its peers
Emeis
PAR:EMEIS
15
CountryFrance
IndustryHealth Care Providers & Services
SizeLarge
Full Stock Analysis →
SHL Telemedicine
SWX:SHLTN
24
CountryIsrael
IndustryHealth Care Providers & Services
SizeX-Small
Full Stock Analysis →
Nano-X Imaging
NMQ:NNOX
26
CountryIsrael
IndustryHealth Care Providers & Services
SizeSmall
Full Stock Analysis →
Cellectis
PAR:ALCLS
19
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Athens Medical Center
ATH:IATR
7
CountryGreece
IndustryHealth Care Providers & Services
SizeSmall
Full Stock Analysis →
SKAN
SWX:SKAN
61
CountrySwitzerland
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →